Close
Achema

Pfizer acquires Baxter’s marketed vaccines portfolio for $635m

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Cryogenic Identification Solutions for Pharma Supply Chains

Maintaining Track-and-Trace Integrity in Extreme Temperature Environments The pharmaceutical industry's...

Predictive AI in Pharma Cold Chain Risk Management

Revolutionizing Cold Chain Management Through Artificial Intelligence The pharmaceutical industry...

Transforming Pharma Cold Chain Using IoT Real-Time Tracking

Transforming Pharmaceutical Cold Chain Through Connected Intelligence The pharmaceutical industry...

Pharma Cold Chain Workforce Competency Frameworks

Building Excellence Through Structured Competency Development The pharmaceutical cold chain...

US-based drug maker Pfizer has completed the acquisition of marketed vaccines portfolio from Baxter International for $635m.

As part of the deal, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are produced.

The portfolio includes NeisVac-C, which helps protect against meningitis caused by group C meningococci (MenC) and FSME-IMMUN / TicoVac that helps protect against brain infection tick-borne encephalitis (TBE).

Pfizer Vaccines president Susan Silbermann said: “NeisVac-C and FSME-IMMUN / Ticovac are a strong fit with our vaccines business and this acquisition adds value, scale and depth to our existing portfolio of innovative vaccines.

“These best-in-class products enable us to reach a broader population with vaccines that prevent infections from serious and often fatal diseases.”

According to Pfizer, FSME-IMMUN / TicoVac received approval in 30 countries and was marketed for more than 30 years, with 120 million doses produced since 1976.

Both companies signed an agreement for the marketed vaccines at the end of July 2014.

Kirkland & Ellis acted as legal advisor to Pfizer, while Credit Suisse Securities (US) served as financial advisor for the company in the transaction.

MenC is a serious infection of the membrane covering the brain. It is one of the most prevalent meningococcal serogroups in many parts of the world, while TBE is an infection of the brain transmitted by the bite of ticks infected with the TBE virus.

Latest stories

Related stories

Cryogenic Identification Solutions for Pharma Supply Chains

Maintaining Track-and-Trace Integrity in Extreme Temperature Environments The pharmaceutical industry's...

Predictive AI in Pharma Cold Chain Risk Management

Revolutionizing Cold Chain Management Through Artificial Intelligence The pharmaceutical industry...

Transforming Pharma Cold Chain Using IoT Real-Time Tracking

Transforming Pharmaceutical Cold Chain Through Connected Intelligence The pharmaceutical industry...

Pharma Cold Chain Workforce Competency Frameworks

Building Excellence Through Structured Competency Development The pharmaceutical cold chain...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back